IQV
IQVIA
$167.81
▲ 0.0%Updated Today 7:15 PM ET
▲ Up 8.5% over the last 12 months
Market Cap
$28.00B
P/E
20.22x
Forward P/E (est.)
18.38x
ROE
22.5%
Revenue Growth
7.3%
EPS Growth
10.0%
Profit Margin
8.3%
FCF Yield
6.8%
Debt / Equity
2.45x
ROIC
10.0%
Interest Coverage
2.99x
Current Ratio
0.75x
Dividend Yield
—
Implied Growth (rev. DCF)
1.6%
Rating Score
51/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what IQV's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. IQV trades near $167.81, below its 50-day average ($173.36) and 200-day average ($195.40). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 38 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. IQV's is $6.41 (~3.8% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month IQV found buyers near $161.75 (support) and sellers near $190.68 (resistance); its 52-week range is $153.01–$247.05. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.1× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
IQVIA (IQV) is a large-cap company in the Life Sciences Tools & Services industry, part of the Health Care sector of the S&P 500, with a market value around $28.00B.
In its latest reported year it generated about $16.31B in revenue and $1.36B in net profit.
Our model rates IQV Neutral (51/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
4.1%
Revenue moved from $13.87B in 2021 to $16.31B in 2025, a 4.1% compound annual growth rate. The most recent year grew a steady 7.3% year over year. Slower, mature growth is common for established businesses.
Gross Margin
33.0%
Operating Margin
13.4%
Net Margin
8.3%
ROE
22.5%
IQVIA keeps about 8.3% of each sales dollar as net profit, with a 33.0% gross margin and 13.4% operating margin. Return on equity is 22.5% and return on invested capital about 10.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$10.78B
Net Debt
$8.84B
Net Debt / EBITDA
4.05x
Debt / Equity
2.45x
Leverage: debt-to-equity is 2.5x, and operating profit covers interest about 3.0x, with a current ratio of 0.8x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $10.78B of total debt against $1.95B of cash.
Operating CF
$2.65B
Free Cash Flow
$2.05B
FCF Margin
12.6%
In the latest year IQVIA produced about $2.65B of operating cash flow and $2.05B of free cash flow after capital spending. That is a free-cash-flow yield of about 6.8% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
20.22x
P/S
1.83x
P/B
5.53x
EV / EBITDA
11.65x
IQV trades at 20.2x trailing earnings (about 18.4x on estimated forward earnings), 1.8x sales, and 5.5x book value. Reverse-engineering today's price implies the market expects roughly 1.6% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How IQV stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), IQV ranks #34 of 59 by our overall rating. It trades at a discount versus the sector on earnings (20.2x P/E vs. 25.4x median) with a higher return on equity (22.5% vs. 14.9%) and slower revenue growth (7.3% vs. 7.9%).
P/E vs sector
20.2x
median 25.4x
ROE vs sector
22.5%
median 14.9%
Growth vs sector
7.3%
median 7.9%
Sector rank
#34
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$131.58 – $219.30
vs. $167.81 today · expected CAGR -5% – 5%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $17.45B | $18.67B | $19.98B | $21.38B | $22.88B |
| Net income | $1.40B | $1.49B | $1.60B | $1.71B | $1.83B |
| EPS | $8.37 | $8.95 | $9.58 | $10.25 | $10.96 |
| Share price (low) | $100.38 | $107.41 | $114.93 | $122.97 | $131.58 |
| Share price (high) | $167.30 | $179.01 | $191.54 | $204.95 | $219.30 |
| CAGR (low–high) | -40% / -0% | -20% / 3% | -12% / 5% | -7% / 5% | -5% / 5% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for IQV:
- Strong return on equity (22.5%) shows capital is put to work well.
- Healthy free-cash-flow yield (~6.8%) funds buybacks and dividends.
The case against IQV:
- Elevated leverage (debt/equity 2.5x) adds financial risk.
- Interest coverage is thin (3.0x), so debt costs bite.
Balance-sheet risk — debt/equity of 2.5x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: IQVIA is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 20.2x earnings, which our model scores Neutral (51/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.